中度大分割质子治疗局限性前列腺癌的前瞻性II期试验四年结果
该前瞻性II期试验纳入184例低至中危局限性前列腺癌患者,接受70 Gy/28次中度大分割质子治疗。中位随访49.2个月,4年生化-临床无失败生存率总体为93.5%,各风险组间无显著差异(log-rank P > .4)。急性≥2级泌尿和胃肠毒性分别为12.5%和3.8%,4年晚期≥2级泌尿和胃肠毒性分别为7.6%和13.6%,患者报告结局无显著长期变化。
要点
- 4年生化-临床无失败生存率总体93.5%,各风险组间无显著差异。
- 急性≥2级泌尿毒性12.5%,胃肠毒性3.8%。
- 4年晚期≥2级泌尿毒性7.6%,胃肠毒性13.6%,均为一过性。
核心结论
- 中度大分割质子治疗局限性前列腺癌与低毒性相关,且未对4年患者报告的泌尿和肠道健康产生负面影响。
研究设计与样本
- 前瞻性II期临床试验,2010至2017年纳入184例低至中危局限性前列腺癌男性,接受70 Gy/28次中度大分割质子治疗。
主要发现
- 中位随访49.2个月,4年生化-临床无失败生存率总体为93.5%(95%CI 89%-98%),低危组94.4%(89%-100%),有利中危组92.5%(86%-100%),不利中危组93.8%(88%-100%),组间log-rank P > .4。
- 急性≥2级胃肠毒性和泌尿毒性发生率分别为3.8%和12.5%。
- 4年晚期≥2级泌尿毒性和胃肠毒性发生率分别为7.6%(4%-13%)和13.6%(9%-20%),报告1例晚期3级胃肠毒性,所有晚期毒性均为一过性。
- 国际前列腺症状评分、国际勃起功能指数问卷和扩展前列腺癌综合指数评分在质子治疗完成后无显著长期变化。
关键数值与推荐
- 处方剂量为70 Gy分28次的中度大分割质子治疗。
- 毒性评估采用美国国家癌症研究所不良事件通用术语标准4.0版。
- 患者报告结局采用国际前列腺症状评分、国际勃起功能指数问卷和扩展前列腺癌综合指数评分。
临床怎么用
- 对于低至中危局限性前列腺癌,中度大分割质子治疗可作为有效且毒性较低的放疗选择。
- 治疗前应告知患者急性泌尿毒性较胃肠毒性更常见,但晚期毒性多为一过性。
- 需进一步开展对比分析以明确质子与光子大分割放疗的差异。
局限性
- 本文未报告随机对照设计,仅为单臂前瞻性II期试验。
- 随访时间有限,中位随访49.2个月,缺乏更长期结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Moderately hypofractionated radiation therapy represents an effective treatment for localized prostate cancer (PC). Although large randomized trials have reported the efficacy of photon-based hypofractionated therapy, hypofractionated proton therapy (HFPT) has not been extensively studied. This study was performed to determine the clinical and patient-reported outcomes for patients with PC treated with HFPT. METHODS AND MATERIALS: Between 2010 and 2017, 184 men were enrolled on a trial of 70 Gy in 28 fractions of HFPT for low- to intermediate-risk PC. Acute and late toxicity was evaluated using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Patient-reported outcomes were measured by International Prostate Symptom Score, International Index of Erectile Function Questionnaire, and Expanded Prostate Cancer Index Composite scores. RESULTS: Median follow-up was 49.2 months. Enrolled patients had low-risk (n = 18), favorable intermediate-risk (n = 78), and unfavorable intermediate-risk (n = 88) PC. Four-year rates of biochemical-clinical failure-free survival were 93.5% (95% confidence interval, 89%-98%), 94.4% (89%-100%), 92.5% (86%-100%), and 93.8% (88%-100%) in the overall group and the low-risk, favorable intermediate-risk, and unfavorable intermediate-risk cohorts, respectively (log-rank P > .4). The incidence of acute grade 2 or higher gastrointestinal (GI) and urologic toxicities were 3.8% and 12.5%, respectively. The 4-year incidence of late grade 2 or higher urologic and GI toxicity was 7.6% (4%-13%) and 13.6% (9%-20%), respectively. One late grade 3 GI toxicity was reported. All late toxicities were transient. Patient-reported International Prostate Symptom, International Index of Erectile Function, and Expanded Prostate Cancer Index Composite scores had no significant long-term changes after completion of HFPT (Supplementary Table 1, available at https://doi.org/10.1016/j.ijrobp.2019.05.069). CONCLUSIONS: HFPT is associated with low rates of toxicity and does not appear to negatively affect 4-year patient reported urinary and bowel health. Further comparative analyses are warranted to better understand differences between proton and photon HFRT.
引用
- Grewal AS, Schonewolf C, Min EJ, et al. Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2019. PMID: 31199994. doi:10.1016/j.ijrobp.2019.05.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。